On August 20, KEYMED BIO-B rose 6.16% in regular trading, trading at 81.95 HKD/share, with turnover of approximately 60.99 million HKD.

The rally was driven by multiple announcements released on August 19. The company's board approved a preliminary plan to issue RMB-denominated shares for listing on the Shanghai Stock Exchange STAR Market, though no application has yet been submitted to regulators. Simultaneously, the company reported H1 interim results showing revenue of 617 million yuan and net profit of 1.218 billion yuan, achieving a historic turnaround from a loss of approximately 79 million yuan in the year-ago period.

The profit swing was primarily attributable to a 1.68 billion yuan pre-tax gain from the disposal of its Ouro Medicines equity stake, recorded within other income of 1.706 billion yuan. Core product Kangyueda continued its commercial ramp, with sales and distribution expenses surging 80% year-over-year. R&D expenses declined 6% to 339 million yuan, while administrative costs fell 4%. The proposed STAR Market listing remains subject to further board approval, shareholder consent, and regulatory clearance.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)